Diligence memo · auto-generated · as of July 2, 2026
Fieldstone Bio, Inc.
Fieldstone Bio, Inc. looks under-valued against its niche peers and is active on financing cadence.
Businessfiled
Fieldstone Bio, Inc. operates in Biotech / Pharma, based in ANDOVER.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Fieldstone Bio, Inc. has raised $5.9M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $5.9M on 2024-12-16.
Most recent recorded round closed around 2024-12-16.
Valuation (modeled)modeled
Provath models Fieldstone Bio, Inc. at approximately $25M (range $6.6M–$48M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.64× the median modeled value of Series A Biotech / Pharma companies in 2022–2024 (21 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 18 mo ago; this sector typically re-raises about every 15 months.
Raising on or ahead of the sector's normal rhythm.
Comparablesmixed
Capital scale ranks ahead of 54% of Biotech / Pharma peers (227 compared).
Modeled value ranks above 47% of those peers.
Closest niche peers: Laxmi Therapeutic Devices, Inc., Accipiter Biosciences Inc., Nanospectra Biosciences Inc, Ten Bay Bio, Inc., Genomic Life, Inc..
Peoplefiled
3 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.